Categories: START-UP

Finnish biopharmaceutical company Desentum closes financial round totalling nearly EUR 2 Million

Desentum, a biopharmaceutical company developing next generation immunotherapy to fight allergies, announced that it has completed a Series A financing round totalling approximately EUR 2 Million. The participating investors include Belgian Cascara Ventures, Luxembourgian ACME Investments, Finnish VTT Ventures and Sto-Rahoitus, and the founding shareholders.

Desentum will use most of the raised capital to produce the most prominent birch pollen hypoallergen under GMP conditions and to prepare for preclinical and clinical trials. The company will also focus on advancing the preclinical research of other respiratory allergens (pollens, animal dander) and developing them into vaccines, as well as securing key intellectual property.

“For the past ten years, the research groups of VTT Technical Research Centre of Finland, University of Eastern Finland and Desentum have collaborated to develop a completely new type of immunotherapy for treating patients suffering from allergies. The therapy is based on using DNA techniques to modify known allergens into so called hypoallergens. The hypoallergens are expected to initiate immunological mechanisms that will protect from allergy. This model has shown excellent results in laboratory tests. If the hypoallergens prove functional in clinical trials as well, we will have a real opportunity to shorten the time needed for allergen immunotherapy and improve the safety of the treatment. The capital raised now will help Desentum to move forward towards first stage clinical trials”, says Pekka Mattila, CEO of Desentum.

Immunotherapy in allergy treatment
 
Allergy is a disorder of the immune system where a normally harmless environmental substance – such as food, pollen or animal dander – causes an allergic reaction. In Europe, 150 million people already suffer from allergies and the number is increasing rapidly. Allergies cause social and economic burden such as health care costs, missed school and work days and impact on the daily lives of the patients.

Allergies are generally managed by medication that alleviates the symptoms. The most common medications are antihistamines and corticosteroids. Immunotherapy is the only treatment currently known that affects the mechanism of allergy. It re-educates the immune system to tolerate the allergen, decreasing the need for medication. Immunotherapy can be administered as injections or sublingual tablets or drops, and the treatment usually takes a few years. The novel immunotherapeutic products that are under development aim for speeding up the treatment as well as improving the safety, efficacy and convenience.

AddThis Website Tools
Liat

Recent Posts

Hi Auto raises $15M to scale conversational AI for quick-service restaurant drive-thrus

Company expands AI order-taking solution to tackle rising labor costs and improve customer experience Hi…

2 days ago

aiOla launches Jargonic, the most accurate speech recognition model for both academic benchmarks and real-world enterprise use

Outperforming competitors like OpenAI and ElevenLabs across standard datasets and specialized jargon recognition, Jargonic sets…

3 days ago

NVIDIA Open Sources Run:ai Scheduler to Foster Community Collaboration

NVIDIA announced KAI Scheduler, the open-source version of the NVIDIA Run:ai Scheduler, available as a…

3 days ago

UK ELECTRIC AIR TAXI SERVICE ON THE HORIZON — Joby and Virgin Atlantic Announce Partnership

Partnership will deliver revolutionary, emissions-free travel in the UK, including greater connectivity for Virgin Atlantic…

3 days ago

DigiKey Announces Sponsorship of KiCad to Support Open-Source EDA Development

DigiKey, a leading global commerce distributor offering the largest selection of technical components and automation…

1 week ago